Severe Paradoxical Reaction During Treatment of Disseminated Tuberculosis in a Patient With Neutralizing Anti-IFNγ Autoantibodies

Interferon-gamma (IFNγ) neutralizing autoantibodies are associated with disseminated nontuberculous mycobacterial infections. We report a previously healthy Thai woman with disseminated tuberculosis and high-titer IFNγ-neutralizing autoantibodies, who developed a severe inflammatory reaction during...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical infectious diseases Vol. 62; no. 6; pp. 770 - 773
Main Authors:	Xie, Yingda L., Rosen, Lindsey B., Sereti, Irini, Barber, Daniel L., Chen, Ray Y., Hsu, Denise C., Qasba, S. Sonia, Zerbe, Christa S., Holland, Steven M., Browne, Sarah K.
Format:	Journal Article
Language:	English
Published:	United States Oxford University Press 15-03-2016
Subjects:	Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Antibodies, Neutralizing - biosynthesis Autoantibodies - blood Autoantibodies - immunology BRIEF REPORTS Female Humans Immunoglobulin G - immunology Inflammation - immunology Inflammation - microbiology Interferon-gamma - blood Interferon-gamma - immunology Middle Aged Mycobacterium Tuberculosis, Miliary - drug therapy Tuberculosis, Miliary - ethnology Tuberculosis, Miliary - immunology United States disseminated tuberculosis IRIS autoantibodies interferon-gamma paradoxical reaction
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Interferon-gamma (IFNγ) neutralizing autoantibodies are associated with disseminated nontuberculous mycobacterial infections. We report a previously healthy Thai woman with disseminated tuberculosis and high-titer IFNγ-neutralizing autoantibodies, who developed a severe inflammatory reaction during anti-tuberculosis treatment. IFNγ contributes to host control of tuberculosis but appears inessential for tuberculosis paradoxical reactions.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Currently at the Division of Vaccines and Related Product Applications, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland.
ISSN:	1058-4838 1537-6591
DOI:	10.1093/cid/civ995